The pathological role of B cells in IBD is in line with a recent report investigating vedolizumab treatment in IBD where a reduction in gut-homing IgG+ and IgA+ PB and a reduced entry of naïve B and T cells into the GALT was demonstrated [38]. This evidence concerns the gene CD79A and inflammatory bowel disease.